Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis

Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis

Background: Telazorlimab is a humanized anti-OX40 monoclonal antibody being studied for treatment of T-cell–mediated diseases. Objective: This randomized, placebo-controlled, phase 2b dose-range finding study investigated efficacy, safety, pharmacokinetics, and immunogenicity of telazorlimab in subj...

Full description

Bibliographic Details
Main Authors: Barbara Rewerska, MD, Lawrence D. Sher, MD, Sady Alpizar, MD, Sylvia Pauser, MD, Grazyna Pulka, MD, Neelufar Mozaffarian, MD, PhD, Yacine Salhi, PhD, Camille Martinet, MS, Wafaa Jabert, MS, Girish Gudi, PhD, Vinu CA, MPharm, MSc, Sunitha GN, PhD, Julie Macoin, MSc, Victor Anstett, MS, Riccardo Turrini, PhD, Marie-Agnès Doucey, PhD, Stanislas Blein, PhD, Cyril Konto, MD, Martina Machkova, MD
Format: Article
Language:English
Published: Elsevier 2024-02-01
Series:Journal of Allergy and Clinical Immunology: Global
Subjects:
Atopic dermatitis
anti-OX40 receptor
humanized monoclonal antibody
phase 2
telazorlimab
Online Access:http://www.sciencedirect.com/science/article/pii/S2772829323001200

Internet

http://www.sciencedirect.com/science/article/pii/S2772829323001200

Similar Items